Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepofarsen in Leber's Congenital Amaurosis (LCA10)
NCT03140969Phase 2Completed
- Sponsor
- Laboratoires Théa
- Start
- Oct 2017
- Primary completion
- Oct 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
A Phase 2 trial of sepofarsen in Leber congenital amaurosis (LCA), sponsored by Laboratoires Théa. Started Oct 2017; status: completed.
02
Drugs
sepofarsen
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT03140969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03140969.